Biomarkers and transcriptome profiling of lung cancer


  • The Authors: Dr Hsuan-Yu Chen is an Assistant Research Fellow at the Institute of Statistical Science, Academia Sinica. His research interests are in bioinformatics, genomic data analysis and development of biosignatures for lung cancer. Dr Sung-Liang Yu is an Associate Professor at the Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University. He specializes in microarray technology, gene expression and microRNA profiling, and functional genomics. Dr Ker-Chau Li is a distinguished Research Fellow of the Institute of Statistical Science, Academia Sinica. His research interests are in statistics and bioinformatics for translational research, and the development of powerful methods for statistical analysis and computing of voluminous genomic data. Dr Pan-Chyr Yang is currently the Dean and Professor of Medicine, National Taiwan University College of Medicine. His major research interests are in pulmonary and critical care medicine, microarray gene expression technology, lung cancer genomics and translational medicine.


Pan-Chyr Yang, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. Email:


Lung cancer is the leading cause of cancer-related deaths worldwide. High-throughput technologies such as microarrays provide an opportunity to explore biomarkers for cancer prevention, prognosis and treatment guidance. Recent studies have revealed many biomarkers with the potential for clinical application. However, major limitations still exist. Although useful data on cancer genomics has accumulated rapidly, there has also been a simultaneous tendency for amplification of the complex relationships among the enormous number of variables that need to be considered. Disentangling these complex gene–gene interactions requires new approaches to data analysis to reveal information that has been obscured by traditional methods. Here, we review the current findings on biomarker identification in lung cancer, address their limitations and discuss some future directions for improvements in this area of research.